中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
6期
467-469
,共3页
癌,非小细胞肺%胸腔积液,恶性%奈达铂%顺铂%治疗效果
癌,非小細胞肺%胸腔積液,噁性%奈達鉑%順鉑%治療效果
암,비소세포폐%흉강적액,악성%내체박%순박%치료효과
Carcinoma,non-small cell lung%Pleural effusion,malignant%Nedaplatin%Cisplatin%Treatment outcome
目的 观察胸腔灌注奈达铂(NDP)与顺铂(DDP)治疗非小细胞肺癌(NSCLC)恶性胸腔积液的疗效、患者的牛活质量及毒副反应.方法 68例确诊为NSCLC(湿性Ⅲb期)的患者,经胸腔置管引流术排尽积液后,随机分为NDP组和DDP组,每组34例.NDP组采用NDP 40 mg/m2和氟美松10 mg溶于40 ml生理盐水,胸腔内灌注;DDP组采用DDP 40 mg/m2和氟美松10 mg溶于40 ml生理盐水,胸腔内灌注.每周1次,连续2～4周.两组患者均给予相同常规支持对症治疗,观察并比较各组的疗效、毒副反应及患者的生活质量.结果 NDP组有效率为88.2%,DDP组有效率为61.7%(P<0.01).NDP组消化道不良反应发生率为5.0%,DDP组消化道不良反应发生率为12.9%,差异有统计学意义(P<0.05).NDP组的Karnofsky评分较DDP组有显著提高(P<0.05),NDP组的患者生存期较DDP组显著延长.结论 NDP胸腔灌注治疗NSCLC引起的恶性胸腔积液是一种有效且毒副反应轻的方法 .
目的 觀察胸腔灌註奈達鉑(NDP)與順鉑(DDP)治療非小細胞肺癌(NSCLC)噁性胸腔積液的療效、患者的牛活質量及毒副反應.方法 68例確診為NSCLC(濕性Ⅲb期)的患者,經胸腔置管引流術排儘積液後,隨機分為NDP組和DDP組,每組34例.NDP組採用NDP 40 mg/m2和氟美鬆10 mg溶于40 ml生理鹽水,胸腔內灌註;DDP組採用DDP 40 mg/m2和氟美鬆10 mg溶于40 ml生理鹽水,胸腔內灌註.每週1次,連續2～4週.兩組患者均給予相同常規支持對癥治療,觀察併比較各組的療效、毒副反應及患者的生活質量.結果 NDP組有效率為88.2%,DDP組有效率為61.7%(P<0.01).NDP組消化道不良反應髮生率為5.0%,DDP組消化道不良反應髮生率為12.9%,差異有統計學意義(P<0.05).NDP組的Karnofsky評分較DDP組有顯著提高(P<0.05),NDP組的患者生存期較DDP組顯著延長.結論 NDP胸腔灌註治療NSCLC引起的噁性胸腔積液是一種有效且毒副反應輕的方法 .
목적 관찰흉강관주내체박(NDP)여순박(DDP)치료비소세포폐암(NSCLC)악성흉강적액적료효、환자적우활질량급독부반응.방법 68례학진위NSCLC(습성Ⅲb기)적환자,경흉강치관인류술배진적액후,수궤분위NDP조화DDP조,매조34례.NDP조채용NDP 40 mg/m2화불미송10 mg용우40 ml생리염수,흉강내관주;DDP조채용DDP 40 mg/m2화불미송10 mg용우40 ml생리염수,흉강내관주.매주1차,련속2～4주.량조환자균급여상동상규지지대증치료,관찰병비교각조적료효、독부반응급환자적생활질량.결과 NDP조유효솔위88.2%,DDP조유효솔위61.7%(P<0.01).NDP조소화도불량반응발생솔위5.0%,DDP조소화도불량반응발생솔위12.9%,차이유통계학의의(P<0.05).NDP조적Karnofsky평분교DDP조유현저제고(P<0.05),NDP조적환자생존기교DDP조현저연장.결론 NDP흉강관주치료NSCLC인기적악성흉강적액시일충유효차독부반응경적방법 .
Objective To compare the therapeutic effects of pleural perfusion of NDP and cDDP in non-small cell lung cancer ( NSCLC) patients with malignant pleural effusion, their quality of life and toxic side effects. Methods Sixty-eight NSCLC patients with malignant pleural effusion after chest drainage were randomly divided into two groups according to the pathological types: 34 cases in the NDP (Group A) and cDDP groups (Group B) , 34 cases each.They were treated with NDP (40 mg/m2) and dexamethasone (10 mg) dissolved in 40 ml normal saline, or cDDP (40 mg/m2) and dexamethasone (10 mg ) dissolved in 40 ml of normal saline, respectively, through pleural perfusion weekly for 2-4 weeks. Routine and symptomatic treatment was used in all the patients.The therapeutic effects, life quality and toxic side effects were evaluated. Results The response rates of groups A and B were 88.23% and 61.7% , respectively, ( P < 0.01). The rates of toxic side effects in groups A and B were 39.6% and 41.9% , respectively, (P > 0.05 ). However, the rates of gastrointestinal side effects of the two groups were 5% and 12. 9% , respectively, ( P < 0.05).The Karnofsky scores of group A were higher than that in group B (P < 0. 05). The survival time of group A was significantly longer than that of group B. Conclusion Pleural perfusion with NDP is a good treatment method with milder toxicity for patients with malignant pleural effusion caused by NSCLC.
